Year Founded
1983
Ownership
Public
Employees
~554
Stage
Commercial
Modalities
Small molecule

OSI Pharmaceuticals General Information

Commercial-stage company with lead product Tarceva (erlotinib) approved for non-small cell lung cancer and pancreatic cancer. Acquired by Astellas in 2010 for $4.0B.

Contact Information

Website
Primary Industry
Biotech
Corporate Office
Melville, New York
United States

Drug Pipeline

erlotinib
Commercial
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to OSI Pharmaceuticals's pipeline data

Book a demo

Key Partnerships

Genentech, Hoffmann-La Roche, Pfizer

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

OSI Pharmaceuticals Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view OSI Pharmaceuticals's complete valuation and funding history, request access »